Privacy Statement   Terms & Conditions   Sitemap  
  Diseases   Research   About us  
Facts & Figures News Career Baxter Worldwide

  Innovation built on experience

Baxter Vaccines continues to look to the future, with its state-of-the-art research centers in Austria dedicated to the prevention of a broad spectrum of infectious disease in infants, children and adults. Currently we have two products on the market: our TBE vaccine and a vaccine against group C meningococcal meningitis.

Baxter International Inc. is a global health care company that, through its subsidiaries, provides critical therapies for people with life-threatening conditions. Baxter’s Bioscience, Medication Delivery and Renal products and services are used to treat patients with some of the most challenging medical conditions including cancer, hemophilia, immuno deficiencies, infectious diseases, kidney disease and trauma. With 2004 sales of $9.5 billion, and approximately 47,000 team members, Baxter is a global leader in developing innovative medical therapies that improve the quality of life for people around the world.

 » Printversion

  » find


Baxter Receives EMEA Positive Opinion for CELVAPAN, the First Cell Culture-based Pandemic Flu Vaccine
» read more

The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine
» read more

U.S. Department of Health and Human Services Completes Funding of 2006 Contract Award to CSC´s DVC and Baxter
» read more

Baxter Vaccines Industriestrasse 67, A-1221 Wien, Tel: +43-1-20100,